Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Expenses (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Accumulated Expenses for 7 consecutive years, with $4.4 million as the latest value for Q1 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $4.4 million in Q1 2025 year-over-year; TTM through Mar 2025 was $4.4 million, a N/A change, with the full-year FY2024 number at $7.7 million, down 11.83% from a year prior.
  • Accumulated Expenses was $4.4 million for Q1 2025 at Fulcrum Therapeutics, down from $7.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.2 million in Q4 2021 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $5.2 million and a median of $4.7 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 49.08% in 2022, then soared 188.14% in 2023.
  • Fulcrum Therapeutics' Accumulated Expenses stood at $9.2 million in 2021, then crashed by 49.08% to $4.7 million in 2022, then skyrocketed by 85.66% to $8.7 million in 2023, then fell by 11.83% to $7.7 million in 2024, then crashed by 43.41% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Accumulated Expenses are $4.4 million (Q1 2025), $7.7 million (Q4 2024), and $8.7 million (Q4 2023).